These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 14687617)
1. T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Aki H; Tuzuner N; Ongoren S; Baslar Z; Soysal T; Ferhanoglu B; Sahinler I; Aydin Y; Ulku B; Aktuglu G Leuk Res; 2004 Mar; 28(3):229-36. PubMed ID: 14687617 [TBL] [Abstract][Full Text] [Related]
2. T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma. Tsirigotis P; Economopoulos T; Rontogianni D; Dervenoulas J; Papageorgiou E; Bollas G; Mantzios G; Kalantzis D; Koumarianou A; Raptis S Oncology; 2001; 61(4):257-64. PubMed ID: 11721171 [TBL] [Abstract][Full Text] [Related]
3. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma]. Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292 [TBL] [Abstract][Full Text] [Related]
4. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382 [TBL] [Abstract][Full Text] [Related]
5. T-cell-rich B-cell lymphoma. A clinicopathologic study of eight cases. Baddoura FK; Chan WC; Masih AS; Mitchell D; Sun NC; Weisenburger DD Am J Clin Pathol; 1995 Jan; 103(1):65-75. PubMed ID: 7817948 [TBL] [Abstract][Full Text] [Related]
7. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center. Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851 [TBL] [Abstract][Full Text] [Related]
8. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082 [TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma]. Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571 [TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
11. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350 [TBL] [Abstract][Full Text] [Related]
13. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992 [TBL] [Abstract][Full Text] [Related]
14. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. Jakobsen LH; Bøgsted M; Brown PN; Arboe B; Jørgensen J; Larsen TS; Juul MB; Schurmann L; Højberg L; Bergmann OJ; Lassen T; Josefsson PL; Jensen P; Johnsen HE; El-Galaly TC J Clin Oncol; 2017 Mar; 35(7):778-784. PubMed ID: 28095160 [TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO; Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141 [TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK; Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337 [TBL] [Abstract][Full Text] [Related]
17. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Gutsch J; Werthmann PG; Rosenwald A; Kienle GS Anticancer Res; 2018 Sep; 38(9):5363-5369. PubMed ID: 30194190 [TBL] [Abstract][Full Text] [Related]
18. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771 [TBL] [Abstract][Full Text] [Related]
19. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. Bouabdallah R; Mounier N; Guettier C; Molina T; Ribrag V; Thieblemont C; Sonet A; Delmer A; Belhadj K; Gaulard P; Gisselbrecht C; Xerri L J Clin Oncol; 2003 Apr; 21(7):1271-7. PubMed ID: 12663714 [TBL] [Abstract][Full Text] [Related]
20. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]